Ferroptosis Validation in Parkinson's Disease

🧫 Experiment Protocol ClinicalParkinson's DiseaseFERROhumanproposed

# Ferroptosis Validation in Parkinson's Disease ## Background and Rationale This clinical validation study investigates ferroptosis as a therapeutic target in Parkinson's disease (PD), building on emerging evidence that iron-dependent lipid peroxidation contributes significantly to dopaminergic neurodegeneration. Ferroptosis, a distinct form of regulated cell death characterized by iron accumulation and lipid peroxidation, has been implicated in PD pathogenesis through multiple mechanisms including α-synuclein-mediated iron dysregulation and mitochondrial dysfunction. The study design incorporates both preclinical validation using PD patient-derived neurons and α-synuclein transgenic models, alongside clinical assessment of ferroptosis biomarkers in PD patients. The experimental approach tests ferroptosis inhibitors including ferrostatin-1, liproxstatin-1, and iron chelators such as deferiprone, evaluating their neuroprotective effects against α-synuclein toxicity and rotenone-induced neurodegeneration. Clinical components involve measuring ferroptosis-related biomarkers including malondialdehyde, 4-hydroxynonenal, and iron metabolism markers in cerebrospinal fluid and plasma from PD patients compared to controls. Advanced techniques include lipidomics analysis to assess lipid peroxidation products and MRI-based iron quantification in substantia nigra. This comprehensive validation will establish ferroptosis as a viable therapeutic target and identify patients most likely to benefit from ferroptosis-targeted interventions. This experiment directly tests predictions arising from the following hypotheses: - **Senescence-Induced Lipid Peroxidation Spreading** - **Mitochondrial Calcium Buffering Enhancement via MCU Modulation** - **Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement** - **TFAM overexpression creates mitochondrial donor-recipient gradients for directed organelle trafficking** - **Mitochondrial Transfer Pathway Enhancement** ## Experimental Protocol **Phase 1: In Vitro Model Development (Months 1-12)** • Establish primary dopaminergic neuronal cultures from human iPSCs differentiated using FOXA2/LMX1A protocol • Generate isogenic PD patient-derived iPSC lines with SNCA, LRRK2, and PRKN mutations (n=30 lines per mutation) • Develop ferroptosis induction protocols using erastin (10-20 μM), RSL3 (1-5 μM), and FIN56 (2-10 μM) • Validate ferroptosis markers: lipid peroxidation (C11-BODIPY), iron accumulation (calcein-AM quenching), GPX4 depletion • Screen ferroptosis inhibitors: ferrostatin-1 (1-10 μM), liproxstatin-1 (1-5 μM), vitamin E (50-200 μM) • Measure ATP production, mitochondrial membrane potential, and ROS levels using fluorometric assays **Phase 2: Biomarker Validation (Months 13-24)** • Recruit early-stage PD patients (n=150, Hoehn-Yahr Stage 1-2, UPDRS-III 10-40) • Recruit age-matched healthy controls (n=75) • Collect cerebrospinal fluid via lumbar puncture and plasma samples • Quantify ferroptosis biomarkers: 4-hydroxynonenal, malondialdehyde, PTGS2, ACSL4 via ELISA/LC-MS • Measure iron levels using inductively coupled plasma mass spectrometry • Assess GPX4 activity and expression via Western blot and qRT-PCR • Correlate biomarker levels with UPDRS-III scores and dopamine transporter SPECT imaging **Phase 3: Phase I Safety Trial (Months 25-30)** • Enroll mild-moderate PD patients (n=24, UPDRS-III 20-50) • Dose-escalation study of ferroptosis inhibitor (ferrostatin-1 analog): 50mg, 100mg, 200mg, 400mg daily • Primary endpoint: maximum tolerated dose and dose-limiting toxicities • Monitor safety labs: CBC, CMP, LFTs, coagulation studies weekly for 4 weeks • Assess pharmacokinetics: plasma and CSF drug levels at 1h, 4h, 8h, 24h post-dose • Document adverse events using CTCAE v5.0 criteria **Phase 4: Phase II Efficacy Trial (Months 31-36)** • Randomized, double-blind, placebo-controlled trial in PD patients (n=120) • Primary efficacy endpoint: change in UPDRS-III score from baseline to 12 weeks • Secondary endpoints: PDQ-39 quality of life, timed up-and-go test, biomarker changes • Administer optimal dose from Phase I study versus placebo for 12 weeks • Neuroimaging: dopamine transporter SPECT at baseline and 12 weeks • Statistical analysis: ANCOVA with baseline score as covariate, significance at p<0.05 ## Expected Outcomes 1. **In vitro ferroptosis induction**: 60-80% neuronal cell death in PD patient-derived cultures treated with erastin/RSL3, with 4-fold increase in lipid peroxidation markers compared to controls (p<0.001) 2. **Biomarker elevation in PD patients**: 2-3 fold higher CSF levels of 4-hydroxynonenal and malondialdehyde in PD patients versus controls, with significant correlation to UPDRS-III scores (r=0.6-0.8, p<0.001) 3. **Phase I safety profile**: Maximum tolerated dose of 200-400mg daily with <20% grade 3-4 adverse events, achieving therapeutic CSF concentrations >1 μM 4. **GPX4 activity reduction**: 40-60% decreased GPX4 activity in PD patient samples compared to controls, with inverse correlation to disease severity (r=-0.5 to -0.7) 5. **Phase II motor improvement**: 15-25% reduction in UPDRS-III scores in treatment group versus <5% in placebo group, with effect size Cohen's d>0.6 6. **Dopamine transporter preservation**: <10% decline in striatal dopamine transporter binding in treatment group versus 15-20% decline in placebo group over 12 weeks ## Success Criteria • **Statistical significance threshold**: Primary endpoints must achieve p<0.05 with appropriate multiple comparison corrections • **Effect size requirements**: Minimum Cohen's d>0.5 for UPDRS-III improvement in Phase II trial, with 80% power to detect 4-point difference • **Safety profile**: <15% serious adverse events in Phase I, no drug-related deaths, and reversible toxicities only • **Biomarker validation**: Area under ROC curve >0.75 for distinguishing PD patients from controls using ferroptosis biomarker panel • **Sample size adequacy**: >90% completion rate in both Phase I (n≥22/24) and Phase II (n≥108/120) trials • **Mechanistic validation**: Significant correlation (r>0.4, p<0.01) between ferroptosis inhibitor plasma levels and biomarker normalization in treated patients

Source: wiki

🧫 Experiment Extras

🟢 Parkinson's Disease 🧠 Neurodegeneration

📊 Evidence Profile

0 supporting 0 contradicting 0 neutral

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found